Cargando…

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy

OBJECTIVE: To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugihara, Koichi, Wakiya, Risa, Shimada, Hiromi, Kameda, Tomohiro, Nakashima, Shusaku, Kato, Mikiya, Miyagi, Taichi, Mizusaki, Mao, Mino, Rina, Nomura, Yumi, Inoo, Masayuki, Kadowaki, Norimitsu, Dobashi, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334253/ https://www.ncbi.nlm.nih.gov/pubmed/35466168 http://dx.doi.org/10.2169/internalmedicine.9223-21

Ejemplares similares

Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study
por: Sugihara, Koichi, et al.
Publicado: (2022)

Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus
por: Wakiya, Risa, et al.
Publicado: (2022)

FDG-PET/CT imaging parameters for predicting spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis
por: Kameda, Tomohiro, et al.
Publicado: (2022)

Systemic lupus erythematosus with various clinical manifestations in a patient with hereditary angioedema: a case report
por: Ushio, Yusuke, et al.
Publicado: (2022)

Pregnancy course and outcomes of patients with polymyositis and dermatomyositis (PM/DM) managed in a single center
por: Mino, Rina, et al.
Publicado: (2022)

Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus
por: Shimada, Hiromi, et al.
Publicado: (2022)

Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose
por: Wakiya, Risa, et al.
Publicado: (2020)

Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report
por: Sugihara, Koichi, et al.
Publicado: (2021)

Factors affecting the Apgar score of offsprings born to mothers suffering from systemic lupus erythematosus
por: Shimada, Hiromi, et al.
Publicado: (2020)

The development of rapidly progressive glomerulonephritis associated with both antineutrophil cytoplasmic antibody-associated vasculitis and anti-glomerular basement membrane nephritis in the course of nontuberculous mycobacterium infection: a case report
por: Kato, Mikiya, et al.
Publicado: (2020)

Squamous Cell Lung Cancer Associated With Systemic Sclerosis
por: Kanaji, Nobuhiro, et al.
Publicado: (2015)

[(18)F] FDG uptake in patients with spondyloarthritis: correlation with serum inflammatory biomarker levels
por: Manabe, Yuri, et al.
Publicado: (2023)

Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report
por: Shimada, Hiromi, et al.
Publicado: (2015)

(18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes
por: Arai-Okuda, Hanae, et al.
Publicado: (2020)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Humoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative Study
por: Alsaed, Omar, et al.
Publicado: (2022)

Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
por: Pri-Paz Basson, Yael, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
por: Udaondo, Clara, et al.
Publicado: (2022)

A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
por: Shimada, Yoshitaka, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab
por: Furer, Victoria, et al.
Publicado: (2022)

Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort
por: Mauro, Daniele, et al.
Publicado: (2022)

Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines
por: Batıbay, Sevilay, et al.
Publicado: (2022)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p95j2m48da227nt23tg8tsetg3